公开(公告)号：US10548866B2

公开(公告)日：2020-02-04

申请号：US13989360

申请日：2011-11-24

申请人： Robin Simon Brooke Williams ,  Matthew Walker

发明人： Robin Simon Brooke Williams ,  Matthew Walker

IPC分类号： A61K31/20

摘要： A compound having the formula (I) R1-COOH wherein R1 is an alkyl or alkenyl group having a C7-11 backbone, optionally branched with a C1-6 alkyl group at any C position in the backbone, or a pharmaceutically acceptable salt, amide or ester thereof, wherein the backbone of the alkyl or alkenyl group, and/or the branched alkyl groups, are optionally interrupted by one or more heteroatoms, provided that when R1 is an alkyl group having a C7 backbone, the branching does not consist only of a hexyl group at the a carbon of R1, or only of a methyl group at the γ carbon of R1, or of only single methyl groups at both the β and ω−1 carbons of R1, and provided that when R1 is an alkyl group having a C8 or C11 backbone, the branching does not consist only of a propyl group at the a carbon of R1, for use in the treatment or prevention of a disease or a biomedical condition selected from seizure-related disorders, bipolar disorders, mania, depression, migraine, attention deficit hyperactivity disorders, latent HIV infection, Alzheimer's disease, chorea, schizophrenia, ischemia, cancer and fatal blood loss.

公开(公告)号：US20130303616A1

公开(公告)日：2013-11-14

申请号：US13989360

申请日：2011-11-24

申请人： Robin Simon Brooke Williams ,  Matthew Walker

发明人： Robin Simon Brooke Williams ,  Matthew Walker

IPC分类号： A61K31/20

摘要： A compound having the formula (I) R1-COOH wherein R1 is an alkyl or alkenyl group having a C7-11 backbone, optionally branched with a C1-6 alkyl group at any C position in the backbone, or a pharmaceutically acceptable salt, amide or ester thereof, wherein the backbone of the alkyl or alkenyl group, and/or the branched alkyl groups, are optionally interrupted by one or more heteroatoms, provided that when R1 is an alkyl group having a C7 backbone, the branching does not consist only of a hexyl group at the a carbon of R1, or only of a methyl group at the γ carbon of R1, or of only single methyl groups at both the β and ω-1 carbons of R1, and provided that when R1 is an alkyl group having a C8 or C11 backbone, the branching does not consist only of a propyl group at the a carbon of R1, for use in the treatment or prevention of a disease or a biomedical condition selected from seizure-related disorders, bipolar disorders, mania, depression, migraine, attention deficit hyperactivity disorders, latent HIV infection, Alzheimer's disease, chorea, schizophrenia, ischemia, cancer and fatal blood loss.

摘要翻译： 具有式（I）R 1 -COOH的化合物，其中R 1是具有C7-11主链的烷基或烯基，任选在主链的任何C位上用C 1-6烷基支链，或其药学上可接受的盐，酰胺 或其酯，其中烷基或烯基和/或支链烷基的主链任选地被一个或多个杂原子中断，条件是当R 1是具有C7主链的烷基时，支链不仅包括 在R 1的碳上的己基或仅在R 1的γ碳上的甲基，或者在R1的β和ω-1碳上仅有单个甲基，并且条件是当R 1是烷基 具有C8或C11骨架的基团，支链不仅仅在R1的碳上由丙基组成，用于治疗或预防选自癫痫发作相关疾病，双相性精神障碍，躁狂症的疾病或生物医学病症 ，抑郁症，偏头痛，注意力缺陷超标 艾滋病毒感染，阿尔茨海默病，舞蹈病，精神分裂症，缺血，癌症和致命性失血。